Vivos to buy 50% stake in SOD Sciences’ pseudohypoxia test
Vivos will receive 50% of the contribution margin from sales of the diagnostic test across all channels.
News
GE HealthCare secures CE mark for MINItrace Magni cyclotron
Centinel Spine gets FDA nod for two-level use of prodisc C Nova
FDA approves Stryker’s Sonopet 3 surgical platform
FDA approves Providence Medical’s CORUS PCSS 3D-T spinal device
Butterfly Medical secures EU MDR certification for BPH implant
Hiossen and GuidedSMILE collaborate on dental implant workflows
First patient treated in Spiro’s PULSAR asthma trial
